VYNE Therapeutics Faces Clinical Hold on VYN202 Program Following Toxicity Findings
VYNE Therapeutics has paused its Phase 1b trial of VYN202 for psoriasis after the FDA imposed a clinical hold due to testicular toxicity observed in non-clinical studies.
Ascletis Enters the Obesity Drug Spotlight with Bold Play on Oral GLP-1 Candidate
Ascletis advances oral GLP-1 drug ASC30 after Phase 1b shows strong weight loss and safety, shifting focus to obesity with a slower dose-escalation strategy.
Pfizer Halts Development of Oral GLP-1 Agonist Danuglipron Amid Liver Safety Signal
Pfizer halts once-daily oral GLP-1 program danuglipron after liver safety concerns, shifting focus to alternative obesity targets including a GIPR antagonist in Phase 2.
The Current and Future State of Personalised Medicine
How precision treatments, AI, and genomics are reshaping healthcare by using advanced technologies to deliver tailored treatments, early diagnoses, and better patient outcomes.
Novo Nordisk Announces Promising Results for CagriSema but Stocks Tell Different Story
REDEFINE 2 Phase 3 trial showed CagriSema led to a 15.7% weight loss in adults with obesity and type 2 diabetes, but the results fell short of expectations, causing a decline in the company's stock value.
Jazz Pharmaceuticals to Acquire Chimerix, Enhancing Oncology Portfolio
The acquisition of Chimerix for $935 million will enhance Jazz’s oncology portfolio, particularly through the addition of dordaviprone, a lead drug candidate for treating a rare and aggressive brain tumor.
